Treating Dry Eye with Ciclosporin 0.09% Practical Guidance for Eye Care Practitioners
Provider: Mivision
Contact: Nikki Byrne, [E] nikki@mivision.com.au, [P] 02 8336 8616
Activity Outline
Here, the authors discuss the use of ciclosporin 0.09% as a treatment option for moderate-to-severe DED, and advise that patient education is key.
The impact of DED on vision, quality of life, and work productivity is considerable, as is the economic burden of the disease, especially indirect costs due to reduced work productivity.
Eye care practitioners are likely to spend an increasing proportion of their time managing patients with dry eye disease (DED) due to the risk of DED increasing with age and an ageing population in general.
Learning Objectives
- Understand why treating underlying inflammation is important in moderate-to-severe dry eye disease for long-term disease management
- Understand the role of ciclosporin 0.09% in the management of moderate-to-severe dry eye disease
- Appreciate the practical considerations including patient education in ciclosporin 0.09% management therapy
- Understand how to use ciclosporin 0.09% for moderate-to-severe dry eye disease in clinical practice for best patient outcomes
Max CPD hours awarded: 1.25
Session Information
| Name |
|---|
| Treating Dry Eye with Ciclosporin 0.09% Practical Guidance for Eye Care Practitioners |
| Clinical? |
| Yes |
| Interactive? |
| No |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 0.75 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 1.25 |